CareDx, Inc. (CDNA) Stock Price & How to Invest

CareDx builds and sells diagnostics, digital tools, and services for the organ-transplant community. Its core products are AlloSure, a next-generation-sequencing test that measures donor-derived cell-free DNA (dd-cfDNA) to detect kidney and heart transplant injury, and AlloMap, a long-established gene-expression test used by the large majority of U.S. heart-transplant centers. Around these tests the company layers patient-management software, pharmacy services, and a research-and-products franchise, positioning itself as an integrated transplant platform rather than a single-test lab.

The investment picture is one of a small-cap growth-plus-turnaround story. Revenue reaccelerated sharply in early 2026 (Q1 up about 39% year over year) and the company posted a rare quarterly profit, while raising full-year guidance and reshaping its portfolio through the Naveris oncology acquisition and the divestiture of its Lab Products unit. The bull case rests on durable testing-volume growth and expanding margins; the bear case centers on reimbursement risk and heavy reliance on the AlloSure and HeartCare franchises. The result is a name with genuine momentum but a valuation that already prices in continued execution.

Reimbursement is the central risk: bears flag potential headwinds of roughly $15 million to $30 million a year from possible coverage or coding changes, which would matter against a revenue base near $413 million. The business is concentrated in the AlloSure and HeartCare franchises, so pricing pressure or a coverage decision there disproportionately affects results. Competition is intensifying, notably from Natera's Prospera test plus Eurofins Transplant Genomics, Devyser, and others, and the rivalry has spilled into litigation. The company remains unprofitable on a trailing-twelve-month basis despite the recent quarterly profit, so the turnaround is early. Integration risk from the Naveris acquisition and execution risk on the Lab Products divestiture add further uncertainty.

A simple financial snapshot. These are approximations and refresh quarterly; for current figures see CareDx, Inc.'s investor relations page or your broker.

• Revenue (TTM): ~$413M
• Q1 2026 revenue: ~$118M (+39% YoY)
• 2026 revenue guidance: ~$447M to $465M
• 2026 adj. EBITDA guidance: ~$43M to $57M
• Net income (TTM): ~-$8M (Q1 2026 positive)
• Market cap: ~$1.1B

CDNA trades at roughly 2.5 to 3 times trailing revenue, a multiple that reflects reaccelerating growth and an early return to profitability rather than deep value. A cash cushion near $200 million and positive adjusted EBITDA guidance give it flexibility, but the trailing net loss means the market is paying for future execution. Reimbursement outcomes are the swing factor for whether the current multiple proves justified.

There are three common ways to get CDNA exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic basket, so CDNA sits alongside other stocks that express the same thesis.

Walnut takes the basket route. Describe a thesis where CDNA fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

CDNA is a focused transplant-testing leader whose growth and newfound profitability are real, but reimbursement dependence and product concentration keep it a higher-risk position.

Whether CDNA is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is CDNA a buy?, and where the stock could go from here in the CDNA stock forecast.

For income investors, whether CDNA pays a dividend and how the payout looks is covered in does CDNA pay a dividend?